Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative.
暂无分享,去创建一个
J. Manson | J. Ockene | Simin Liu | J. Wactawski‐Wende | J. Curb | J. Berger | I. Ockene | F. Thomas | R. Balasubramanian | Yunsheng Ma | B. Olendzki | P. Merriam | Y. Qiao | A. Culver | Deidre M. Sepavich | Catherine Rahilly-Tierny | Fridtjof Thomas
[1] Paul Welsh,et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.
[2] P. Barter,et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. , 2011, Journal of the American College of Cardiology.
[3] Issa J Dahabreh,et al. Index event bias as an explanation for the paradoxes of recurrence risk research. , 2011, JAMA.
[4] G. Guyatt,et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. , 2011, QJM : monthly journal of the Association of Physicians.
[5] V. Basevi. Standards of Medical Care in Diabetes—2011 , 2011, Diabetes Care.
[6] D. Mozaffarian,et al. Association Between Adiposity in Midlife and Older Age and Risk of Diabetes in Older Adults , 2010 .
[7] R. Simpson,et al. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. , 2010, Journal of clinical lipidology.
[8] M. Kivimäki,et al. Self-report as an indicator of incident disease. , 2010, Annals of epidemiology.
[9] I. Janssen,et al. Testosterone and Visceral Fat in Midlife Women: The Study of Women's Health Across the Nation (SWAN) Fat Patterning Study , 2010, Obesity.
[10] Yasuo Ohashi,et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.
[11] Paul M. Ridker,et al. Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis , 2009, Diabetes Care.
[12] K. Yokote,et al. Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). , 2009, Journal of atherosclerosis and thrombosis.
[13] Weiping Jia,et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. , 2009, JAMA.
[14] K. Reynolds,et al. Trends in Statin Use and Low-Density Lipoprotein Cholesterol Levels Among US Adults: Impact of the 2001 National Cholesterol Education Program Guidelines , 2008, The Annals of pharmacotherapy.
[15] Jennifer G. Robinson,et al. Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements , 2008, Clinical trials.
[16] Curt D. Furberg,et al. Lipoprotein Management in Patients With Cardiometabolic Risk , 2008, Diabetes Care.
[17] S. Feasson,et al. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .
[18] Samia Mora,et al. Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. , 2007, European heart journal.
[19] J. Shaw,et al. Insulin Sensitivity and Insulin Secretion Determined by Homeostasis Model Assessment and Risk of Diabetes in a Multiethnic Cohort of Women: the Women’s Health Initiative Observational Study , 2007, Diabetes Care.
[20] J. Manson,et al. A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women. , 2007, Archives of internal medicine.
[21] E. Ding,et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. , 2006, JAMA.
[22] G. Heiss,et al. The effect of conjugated equine oestrogen on diabetes incidence: the Women’s Health Initiative randomised trial , 2006, Diabetologia.
[23] C. Kooperberg,et al. Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. , 2004, American journal of epidemiology.
[24] Douglas W Mahoney,et al. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. , 2004, Journal of clinical epidemiology.
[25] A. Gotto,et al. Update on Statins: 2003 , 2004, Circulation.
[26] Neil J Stone,et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.
[27] B. Howard,et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial , 2004, Diabetologia.
[28] P. Mason. Update on statins. , 2004, Intensive & critical care nursing.
[29] R. Chlebowski,et al. The Women's Health Initiative Dietary Modification trial: overview and baseline characteristics of participants. , 2003, Annals of epidemiology.
[30] R. Langer,et al. The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. , 2003, Annals of epidemiology.
[31] Susan R. Johnson,et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. , 2003, Annals of epidemiology.
[32] C. Kooperberg,et al. Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study. , 2003, JAMA.
[33] Sarah Parish,et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.
[34] T. Sudhop,et al. Pharmacology of 3‐Hydroxy‐3‐Methylglutaryl‐Coenzyme A Reductase Inhibitors (Statins), Including Rosuvastatin and Pitavastatin , 2002, Journal of clinical pharmacology.
[35] A. Kristal,et al. Measurement characteristics of the Women's Health Initiative food frequency questionnaire. , 1999, Annals of epidemiology.
[36] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[37] Donald Rubin,et al. Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.
[38] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[39] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[40] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[41] P. Toth. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis , 2012 .
[42] C. White,et al. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. , 2010, Diabetes research and clinical practice.
[43] N. Unwin,et al. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .
[44] B. Kestenbaum,et al. Calcium plus vitamin D supplementation and the risk of incident diabetes mellitus in the Women ’ s Health Initiative , 2008 .
[45] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[46] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[47] HOMAS,et al. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .
[48] JoAnn E. Manson,et al. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. , 1998, Controlled clinical trials.